Screening for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography - a prospective, cross sectional study
- PMID: 32839076
- DOI: 10.1016/j.ejim.2020.08.005
Screening for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography - a prospective, cross sectional study
Abstract
Aim: To investigate the prevalence and severity of nonalcoholic fatty liver disease (NAFLD) in patients with diabetes mellitus type 2 (T2DM), based on increased controlled attenuation parameter (CAP) and liver stiffness measurements obtained by transient elastography. In addition, we aimed to identify parameters that correlate with increased elastographic parameters of steatosis and fibrosis to provide a better indication when a patient with T2DM should be screened for NAFLD.
Methods: We conducted prospective, cross-sectional study of 679 consecutive adult patients with diagnosed T2DM mean age 65.2±11.6. NAFLD was defined by transient elastography. In 105 patients a percutaneous liver biopsy (LB) was done.
Results: The prevalence of NAFLD based on transient elastography was 83.6%. Independent factors associated with increased CAP were higher body mass index, longer T2DM duration, higher serum triglyceride, lower levels of vitamin D, higher C-reactive protein, and higher HOMA-IR. The prevalence of moderate liver fibrosis was 26.9% and advanced liver fibrosis 12.6%. Independent factors associated with moderated fibrosis based on elastography were higher body mass index and higher levels of alanine aminotransferase (ALT), while independent factors associated with advanced fibrosis were female gender, higher body mass index, higher levels of ALT, gama-glutamil transferase and C-reactive protein. Sixty-four (60.9%) of 105 patients with LB had NAFLD activity score ≥5. Regarding the presence and stages of fibrosis based on LB, moderate fibrosis was found in 29.5% of patients, while 29.5% had advanced fibrosis and 6.7% cirrhosis.
Conclusion: This study supports more aggressive screening for NAFLD and fibrosis in patients with T2DM.
Keywords: Advanced fibrosis; Diabetes mellitus type 2; Moderate fibrosis; Nonalcoholic fatty liver disease; Screening.
Copyright © 2020 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.J Gastroenterol Hepatol. 2019 Aug;34(8):1396-1403. doi: 10.1111/jgh.14577. Epub 2019 Jan 21. J Gastroenterol Hepatol. 2019. PMID: 30551263
-
Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes: Evidence from the CORDIAL cohort study.Saudi J Gastroenterol. 2022 Nov-Dec;28(6):426-433. doi: 10.4103/sjg.sjg_73_22. Saudi J Gastroenterol. 2022. PMID: 35645140 Free PMC article.
-
Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus.PLoS One. 2020 Aug 21;15(8):e0236977. doi: 10.1371/journal.pone.0236977. eCollection 2020. PLoS One. 2020. PMID: 32822391 Free PMC article.
-
Current and Emerging Biomarkers and Imaging Modalities for Nonalcoholic Fatty Liver Disease: Clinical and Research Applications.Clin Ther. 2021 Sep;43(9):1505-1522. doi: 10.1016/j.clinthera.2021.07.012. Epub 2021 Aug 13. Clin Ther. 2021. PMID: 34400007 Review.
-
Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association.Diabetes Metab J. 2020 Jun;44(3):382-401. doi: 10.4093/dmj.2020.0010. Epub 2020 May 11. Diabetes Metab J. 2020. PMID: 32431115 Free PMC article. Review.
Cited by
-
Assessment of Steatosis and Fibrosis in Liver Transplant Recipients Using Controlled Attenuation Parameter and Liver Stiffness Measurements.Can J Gastroenterol Hepatol. 2021 Feb 8;2021:6657047. doi: 10.1155/2021/6657047. eCollection 2021. Can J Gastroenterol Hepatol. 2021. PMID: 33628759 Free PMC article.
-
Efficacy and safety of Jian-Pi Huo-Xue granule for non-alcoholic fatty liver disease: study protocol for a randomized, double-blind, placebo-controlled trial.Trials. 2022 Jun 2;23(1):455. doi: 10.1186/s13063-022-06393-8. Trials. 2022. PMID: 35655225 Free PMC article.
-
Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus.Cureus. 2021 Aug 20;13(8):e17321. doi: 10.7759/cureus.17321. eCollection 2021 Aug. Cureus. 2021. PMID: 34557367 Free PMC article. Review.
-
Surveillance of the liver in type 2 diabetes: important but unfeasible?Diabetologia. 2024 Jun;67(6):961-973. doi: 10.1007/s00125-024-06087-7. Epub 2024 Feb 9. Diabetologia. 2024. PMID: 38334817 Free PMC article. Review.
-
Referral care paths for non-alcoholic fatty liver disease-Gearing up for an ever more prevalent and severe liver disease.United European Gastroenterol J. 2021 Oct;9(8):903-909. doi: 10.1002/ueg2.12150. Epub 2021 Oct 5. United European Gastroenterol J. 2021. PMID: 34609086 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous